Home Cart Sign in  
Chemical Structure| 1793053-37-8 Chemical Structure| 1793053-37-8

Structure of LLY-507
CAS No.: 1793053-37-8

Chemical Structure| 1793053-37-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LLY-507 is a potent and selective protein-lysine methyltransferase SMYD2 inhibitor with IC50 <15 nM, which can inhibit p53K370 monomethylation in cells with an IC50 ~600 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LLY-507

CAS No. :1793053-37-8
Formula : C36H42N6O
M.W : 574.76
SMILES Code : O=C(C1=CC(C2=CC=CC=C2N3CCN(CCN4C=C(C)C5=C4C=CC=C5)CC3)=CC(C#N)=C1)NCCCN6CCCC6
MDL No. :MFCD28902312
InChI Key :PNYRDVBFYVDJJI-UHFFFAOYSA-N
Pubchem ID :91623361

Safety of LLY-507

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of LLY-507

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
U2OS cells 0–25 μM 15 hours To examine the inhibitory effect of LLY-507 on SMYD2-induced monomethylation of p53 Lys370, IC50 0.6 μM. PMC4447944
KYSE-150 cells overexpressing SMYD2 5 μM 24 hours SILAC-based quantitative proteomics revealed down-regulation of 258 Kme1 sites PMC4813708
Esophageal squamous cell carcinoma (ESCC) cells (KYSE-150) 5 μM 24 hours To evaluate the inhibitory effect of LLY-507 on SMYD2 activity, showing significant reduction in p53-K370me1 levels PMC4813708
KYSE-150 cells 0–5 μM 24 hours To examine the inhibitory effect of LLY-507 on SMYD2-induced monomethylation of p53 Lys370, IC50 0.6 μM. PMC4447944
HEK293 cells 0–2.5 μM 28 hours To examine the inhibitory effect of LLY-507 on SMYD2-induced monomethylation of p53 Lys370, IC50 less than 1 μM. PMC4447944
Human aortic smooth muscle cells (HASMCs) 2 μM 48 hours Inhibited HASMC proliferation, as evidenced by reduced cell number, cell viability, and number of EdU- or Ki67-positive HASMCs. PMC10840433
IWAT-SVF cells 10 μM 6 days Inhibited adipocyte differentiation, reduced lipid droplet formation, and decreased expression of adipogenesis markers (PPARγ, C/EBPα, FABP4) PMC9586978
3T3-L1 preadipocytes 10 μM 6 days Inhibited adipocyte differentiation, reduced lipid droplet formation, and decreased expression of adipogenesis markers (PPARγ, C/EBPα, FABP4) PMC9586978
A549 cells 11.5 µg/mL to 0.08 µg/mL 72 hours To evaluate the cytotoxicity of LLY-507 alone and LLY-507-loaded IONPs against A549 cells. Results showed IC50 values of 0.71 µg/mL for LLY-507 alone and 0.53 µg/mL for LLY-507-loaded IONPs, indicating stronger synergistic anticancer potential of the loaded nanoparticles. PMC10384399
HESCs and hiPSCs 10 nM 9 days High-efficiency induction of hPSC-MSCs generation, meeting the multifaceted characteristics of MSCs PMC7787598

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Carotid artery injury-induced neointimal hyperplasia model Intraperitoneal injection 1 mg/kg/day Once daily for 28 days Significantly inhibited carotid artery injury-induced neointima formation, reduced PCNA expression, and increased α-SMA and SM22α expression. PMC10840433
BALB-c mice Urethane-induced non-small cell lung cancer model Intravenous injection 30 mg/kg Three days with 24-hour intervals To evaluate the therapeutic effect of LLY-507-loaded IONPs in a urethane-induced lung cancer model. Results showed that LLY-507-loaded IONPs significantly inhibited SMYD2 expression, reduced emphysema, hemorrhage, and tumor growth, and restored p53 expression. PMC10384399

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.74mL

0.35mL

0.17mL

8.70mL

1.74mL

0.87mL

17.40mL

3.48mL

1.74mL

References

 

Historical Records

Categories